Anti-GAD65 antibodies can lead to a decrease in the concentration of GABA in the brain, which can lead to a state of hyperexcitability of the CNS, which in turn can lead to a range of clinical manifestations such as limbic encephalitis, epilepsy, stiff-person syndrome, cerebellar ataxia, spinal cord disease and/or brainstem dysfunction [2]. This study details the diagnostic and therapeutic approach employed in two cases of epilepsy associated with anti-GAD65 antibodies, which presented with diplopia. The gene discussed is GAD2; the disease is aceruloplasminemia.